

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Town Health International Medical Group Limited
康健國際醫療集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 3886)

**APPOINTMENT OF
EXECUTIVE DIRECTOR AND DEPUTY CHAIRMEN**

The Board is pleased to announce that with effect from 22 December 2022, Mr. Liu Gefeng has been appointed as an executive Director and a Deputy Chairman, and Dr. Tsang Wah Tak, Kenneth, an executive Director, has been appointed as a Deputy Chairman.

**APPOINTMENT OF EXECUTIVE DIRECTOR AND DEPUTY
CHAIRMAN**

The board (“**Board**”) of directors (“**Directors**”) of Town Health International Medical Group Limited (“**Company**”, together with its subsidiaries as, the “**Group**”) is pleased to announce that Mr. Liu Gefeng (“**Mr. Liu**”) has been appointed as an executive Director and a deputy chairman of the Company (“**Deputy Chairman**”) with effect from 22 December 2022.

The biographical details of Mr. Liu are set out below:

Mr. Liu, aged 56, obtained his bachelor’s degree in economics and master’s degree in economics from the Renmin University of China (中國人民大學) in July 1989 and January 1999, respectively.

Mr. Liu worked at 中國青少年讀物發行總公司 (in English, for identification purpose only, China Youngster's Books Publishing Corporation) from October 1989 to June 1992. During the period from June 1992 to May 2000, Mr. Liu worked at various financial institutions in the People's Republic of China ("PRC"), including China CITIC Bank (中信實業銀行), Hainan Machinery Trust Investment Company (海南機設信託投資公司), Shenyin & Wanguo Securities Company Limited (申銀萬國證券有限公司) and Zhong Bao Trust Investments Company (中保信託投資公司). Mr. Liu worked at China Life Insurance (Group) Company (中國人壽保險(集團)公司) ("**China Life Insurance**") from May 2000 to September 2003 and China Life Insurance Company Limited (中國人壽保險股份有限公司) from September 2003 to September 2022, with his last position at the latter being deputy general manager of the investment management center. Mr. Liu has been appointed as a member of the management committee of China Life Private Equity Investment Company Limited (國壽股權投資有限公司) ("**China Life Private Equity**") since September 2022. As at the date of this announcement, China Life Private Equity is a wholly-owned subsidiary of China Life Insurance, a substantial shareholder (having the meaning ascribed to it in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**")) of the Company.

Mr. Liu was appointed as an assistant to the director of the Development and Reform Commission of Guangxi Zhuang Autonomous Region (廣西壯族自治區發改委) from October 2013 to November 2015. Mr. Liu was appointed as the deputy director of the management committee of the Tianjin Port Free Trade Zone (天津港保稅區管理委員會) from November 2015 to December 2017.

Mr. Liu has entered into a letter of appointment with the Company as an executive Director and a Deputy Chairman for a term commencing from 22 December 2022 to 31 December 2024. He will enter into a service contract with the Group for a term of two years. As a Director, Mr. Liu will be subject to rotation and re-election at general meeting of the Company in accordance with the bye-laws of the Company. Mr. Liu will be entitled to an emolument of HK\$20,000 per month for holding office as an executive Director and a Deputy Chairman, and also a basic salary of HK\$180,000 per month and a discretionary bonus under the service contract, both of which are recommended by the remuneration committee ("**Remuneration Committee**") of the Board and approved by the Board. All such emoluments are determined with reference to the Company's remuneration policy, the prevailing market conditions, Mr. Liu's duties and responsibilities as well as his performance.

Save as disclosed above, as at the date of this announcement, Mr. Liu does not (i) hold any other position with the Company or other members of the Group; and (ii) hold any other major appointment and professional qualification.

As at the date of this announcement, Mr. Liu (i) did not hold any directorship in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not have any interests in the shares of the Company (“Shares”) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong (“SFO”)); and (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meanings ascribed to them in the Listing Rules) of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Liu as an executive Director and a Deputy Chairman that need to be brought to the attention of the shareholders of the Company.

APPOINTMENT OF DEPUTY CHAIRMAN

The Board further announces that Dr. Tsang Wah Tak, Kenneth (“**Dr. Tsang**”), an executive Director, has been appointed as a Deputy Chairman with effect from 22 December 2022.

The biographical details of Dr. Tsang are set out below:

Dr. Tsang, aged 61, was appointed as an executive Director on 11 November 2022 and a member of each of the Remuneration Committee and the nomination committee of the Board on 12 December 2022. Dr. Tsang obtained the bachelor’s degree in Medicine and Surgery in July 1986 and the degree of Doctor of Medicine in December 1995 from the University of Glasgow. Dr. Tsang has become a registered medical practitioner by the Medical Council of Hong Kong since 1996. Dr. Tsang was elected to the Membership of the Royal Colleges of Physicians of the United Kingdom in November 1989, as a Fellow by Hong Kong College of Physicians in January 1996, as a Fellow by the Hong Kong Academy of Medicine in the specialty of Medicine in October 1996, as a Collegiate Member of the Royal College of Physicians and Surgeons of Glasgow in July 2000, as a Physician Fellow of the Royal College of Physicians and Surgeons of Glasgow in March 2001, to the Fellowship of Royal College of Physicians of London in May 2001, as a Fellow of the American College of Chest Physicians in October 1997 and the American College of Clinical Pharmacology in February 1998. Dr. Tsang has been accredited in Respiratory Medicine from August 1993 and in Internal Medicine from July 1994 by the Hong Kong College of Physicians. Dr. Tsang is also currently a director of a number of subsidiaries of the Company.

Dr. Tsang was an Associate Editor in Respiriology. Dr. Tsang was appointed as Adjunct Professor in the Faculty of Health and Social Sciences at The Hong Kong Polytechnic University from November 2005 to October 2007, and was appointed as a Section Head in the Respiratory Disorders Faculty of Faculty of 1000 Medicine. Dr. Tsang was appointed as the Chairman of the Hong Kong Lung Foundation from 2007 to 2009 and has been an Executive Board Member of the Hong Kong Lung Foundation since 2009. Dr. Tsang was appointed as the President of the Hong Kong Thoracic Society from 2001 to 2003, and is currently a Council Member of the Hong Kong Thoracic Society. Dr. Tsang has been appointed as the Vice-President of The Society of Physicians of Hong Kong since 2008. Dr. Tsang has been a member of the Grant Review Board of the Health and Medical Research Fund Research Council since October 2003. Dr. Tsang was a Distinguished Professor at Guangzhou Medical University (formerly known as Guangzhou Medical College) in the PRC from November 2011 to November 2014. Dr. Tsang has been appointed as Honorary Clinical Professor in the Department of Medicine at The University of Hong Kong since 2013. Dr. Tsang has been registered as Specialist in Respiratory Medicine since March 1998.

Dr. Tsang was a director of (i) Pegasus Investments Limited, a private company incorporated in Hong Kong and dissolved by deregistration on 22 April 2022 under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (“**Chapter 622**”); (ii) Pixel Investments Limited, a private company incorporated in Hong Kong and dissolved by deregistration on 14 April 2022 under Chapter 622; (iii) Sharp Wealthy Limited, a private company incorporated in Hong Kong and dissolved by deregistration on 3 November 2017 under Chapter 622; (iv) Hong Kong Medical Specialists Limited, a private company incorporated in Hong Kong and dissolved by deregistration on 23 September 2016 under Chapter 622; and (v) University Medical Specialists Limited, a private company incorporated in Hong Kong and dissolved by deregistration on 22 July 2011 under the then prevailing Companies Ordinance (Chapter 32 of the Laws of Hong Kong). Dr. Tsang has confirmed that Pegasus Investments Limited, Pixel Investments Limited, Sharp Wealthy Limited, Hong Kong Medical Specialists Limited and University Medical Specialists Limited were inactive and solvent prior to their dissolution, and there was no wrongful act on his part leading to the dissolution of such companies, and that he is not aware of any actual or potential claim that has been or will be made against him as a result of their dissolution.

In light of his appointment as a Deputy Chairman, Dr. Tsang has entered into a new letter of appointment (“**New Appointment Letter**”) with the Company as an executive Director and a Deputy Chairman for a term commencing from 22 December 2022 to 31 December 2024, as replacement of his letter of appointment with the Company. Dr. Tsang will be subject to rotation and re-election at general meeting of the Company in accordance with the bye-laws of the Company. Pursuant to the New Appointment Letter, Dr. Tsang is entitled to an emolument of HK\$20,000 per month which was determined by the Board with reference to his duties and responsibilities with the Company, the Company’s remuneration policy and the prevailing market conditions.

As at the date of this announcement, Dr. Tsang confirmed that he has interest in 141,879,000 underlying Shares within the meaning of Part XV of the SFO.

Save as disclosed above, as at the date of this announcement, Dr. Tsang (i) does not hold any other position with the Company or other members of the Group; (ii) does not hold any other major appointment and professional qualification; and (iii) does not have any interests in the Shares within the meaning of Part XV of the SFO.

As at the date of this announcement, Dr. Tsang (i) did not hold any directorship in the last three years in any public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (ii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meaning ascribed to them in the Listing Rules) of the Company.

Save as disclosed above, there is no further information to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the appointment of Dr. Tsang as a Deputy Chairman that need to be brought to the attention of the shareholders of the Company.

Following the appointment of Mr. Liu, the number of independent non-executive Directors remains below one-third of the Board as required under Rule 3.10(A) of the Listing Rules. The Company will identify suitable candidates to fill the vacancies as soon as possible. Further announcement will be made by the Company when the relevant appointments are made.

The Board would like to express its warmest welcome to Mr. Liu and Dr. Tsang on their new appointments.

By Order of the Board
Town Health International Medical Group Limited
Jin Zhaogen
Executive Director and Chief Executive Officer

22 December 2022

As at the date of this announcement, the executive Directors are Mr. Jin Zhaogen (Chief Executive Officer), Ms. Zhao Xiangke (Chief Financial Officer), Dr. Wong Chi Kit Nelson, Dr. Law Kwan Kin, Dr. Wong Chun Wa, Mr. Ng Ting Chi, Ms. Yao Yuan, Ms. Lau Wai Yee, Susanna, Dr. Tsang Wah Tak, Kenneth (Deputy Chairman), Mr. Shiu Shu Ming and Mr. Liu Gefeng (Deputy Chairman); the non-executive Directors are Mr. Kong Dechang (Chairman) and Mr. Hou Jun; and the independent non-executive Directors are Mr. Ho Kwok Wah, George, MH, Mr. Yu Xuezhong, Dr. Xu Weiguo, Mr. Chui Tsan Kit and Mr. Han Wenxin.